GERN Geron Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: GERN

Price (delayed)

$3.69

Market cap

$2.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.32

Enterprise value

$2.03B

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two ...

Highlights
Geron's EPS has increased by 14% YoY and by 9% from the previous quarter
The quick ratio has grown by 35% YoY but it has contracted by 15% from the previous quarter
The revenue has plunged by 60% YoY and by 25% from the previous quarter
The company's gross profit has shrunk by 60% YoY and by 25% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.geron.com
Peers: GILD STEM TECH INCY

Key stats

What are the main financial stats of GERN
Market
Shares outstanding
546.06M
Market cap
$2.01B
Enterprise value
$2.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.08
Price to sales (P/S)
8,884.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,564.22
Earnings
Revenue
$237,000
EBIT
-$175.82M
EBITDA
-$174.78M
Free cash flow
-$168.57M
Per share
EPS
-$0.32
Free cash flow per share
-$0.3
Book value per share
$0.46
Revenue per share
$0
TBVPS
$0.69
Balance sheet
Total assets
$394.08M
Total liabilities
$146.13M
Debt
$85.9M
Equity
$247.95M
Working capital
$233.28M
Liquidity
Debt to equity
0.35
Current ratio
3.16
Quick ratio
3.11
Net debt/EBITDA
-0.08
Margins
EBITDA margin
-73,747.7%
Gross margin
100%
Net margin
-77,690.7%
Operating margin
-81,832.9%
Efficiency
Return on assets
-44.7%
Return on equity
-63.3%
Return on invested capital
-53.5%
Return on capital employed
-61.5%
Return on sales
-74,183.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GERN stock price

How has the Geron stock price performed over time
Intraday
5.43%
1 week
0.27%
1 month
11.48%
1 year
39.25%
YTD
74.88%
QTD
11.82%

Financial performance

How have Geron's revenue and profit performed over time
Revenue
$237,000
Gross profit
$237,000
Operating income
-$193.94M
Net income
-$184.13M
Gross margin
100%
Net margin
-77,690.7%
The revenue has plunged by 60% YoY and by 25% from the previous quarter
The company's gross profit has shrunk by 60% YoY and by 25% QoQ
The operating margin has declined by 43% since the previous quarter
GERN's net margin is down by 41% since the previous quarter

Growth

What is Geron's growth rate over time

Valuation

What is Geron stock price valuation
P/E
N/A
P/B
8.08
P/S
8,884.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8,564.22
Geron's EPS has increased by 14% YoY and by 9% from the previous quarter
The P/B is 107% above the 5-year quarterly average of 3.7 and 78% above the last 4 quarters average of 4.3
Geron's equity has decreased by 15% from the previous quarter
The P/S is 121% above the last 4 quarters average of 3812.9
The revenue has plunged by 60% YoY and by 25% from the previous quarter

Efficiency

How efficient is Geron business performance
GERN's ROE has soared by 52% year-on-year and by 10% since the previous quarter
Geron's ROS has decreased by 41% from the previous quarter
Geron's ROIC has increased by 40% YoY and by 10% from the previous quarter
The ROA has grown by 32% YoY and by 8% from the previous quarter

Dividends

What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GERN.

Financial health

How did Geron financials performed over time
Geron's total assets is 170% higher than its total liabilities
Geron's total assets has surged by 107% YoY but it has decreased by 4.6% QoQ
The quick ratio has grown by 35% YoY but it has contracted by 15% from the previous quarter
GERN's debt is 65% smaller than its equity
GERN's debt to equity has soared by 84% QoQ but it has shrunk by 50% YoY
GERN's debt has surged by 54% year-on-year and by 53% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.